Confo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 66

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $65M

  • Investors
  • 19

Confo Therapeutics General Information

Description

Developer of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies that stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry with novel agonists for improved therapeutic intervention.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Technologiepark 30
  • Zwijnaarde
  • 9052 Ghent
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Technologiepark 30
  • Zwijnaarde
  • 9052 Ghent
  • Belgium

Confo Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Confo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series B) 26-Jul-2024 $65M Completed Clinical Trials - Phase 1
10. Grant 28-Mar-2024 Completed Clinical Trials - Phase 1
9. Grant 28-Jun-2022 Completed Clinical Trials - Phase 1
8. Grant 30-Mar-2021 Completed Clinical Trials - Phase 1
7. Grant 20-Jun-2019 Completed Clinical Trials - Phase 1
6. Early Stage VC (Series A) 01-May-2019 Completed Clinical Trials - Phase 1
5. Grant 20-Feb-2018 Completed Clinical Trials - Phase 1
4. Grant 01-Feb-2017 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Feb-2016 $7.28M $7.28M Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2015 Completed Startup
To view Confo Therapeutics’s complete valuation and funding history, request access »

Confo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B2
Class B
To view Confo Therapeutics’s complete cap table history, request access »

Confo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a
Drug Discovery
Ghent, Belgium
66 As of 2024

South San Francisco, CA
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confo Therapeutics Competitors (89)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Inhibrx Formerly VC-backed La Jolla, CA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Agenus Formerly VC-backed Lexington, MA
InterAx Venture Capital-Backed Villigen, Switzerland
You’re viewing 5 of 89 competitors. Get the full list »

Confo Therapeutics Patents

Confo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3227194-A1 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling Pending 30-Jul-2021
AU-2022318349-A1 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling Pending 30-Jul-2021
EP-4377307-A1 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling Pending 30-Jul-2021
EP-3963328-A1 Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs Pending 29-Apr-2019
EP-3963329-A1 Screening methods and assays for use with transmembrane proteins, in particular with gpcrs Pending 29-Apr-2019 G01N33/566
To view Confo Therapeutics’s complete patent history, request access »

Confo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confo Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ackermans & van Haaren Growth/Expansion Minority
Driehaus Capital Management Corporation Minority
Quest For Growth Asset Manager Minority
BioGeneration Ventures Venture Capital Minority
Fund+ Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Confo Therapeutics FAQs

  • When was Confo Therapeutics founded?

    Confo Therapeutics was founded in 2015.

  • Where is Confo Therapeutics headquartered?

    Confo Therapeutics is headquartered in Ghent, Belgium.

  • What is the size of Confo Therapeutics?

    Confo Therapeutics has 66 total employees.

  • What industry is Confo Therapeutics in?

    Confo Therapeutics’s primary industry is Drug Discovery.

  • Is Confo Therapeutics a private or public company?

    Confo Therapeutics is a Private company.

  • What is Confo Therapeutics’s current revenue?

    The current revenue for Confo Therapeutics is .

  • How much funding has Confo Therapeutics raised over time?

    Confo Therapeutics has raised $105M.

  • Who are Confo Therapeutics’s investors?

    Ackermans & van Haaren, Driehaus Capital Management, Quest For Growth, BioGeneration Ventures, and Fund+ are 5 of 19 investors who have invested in Confo Therapeutics.

  • Who are Confo Therapeutics’s competitors?

    CytomX Therapeutics, Inhibrx, CRISPR Therapeutics, Agenus, and InterAx are some of the 89 competitors of Confo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »